New hope for patients with hard-to-treat autoimmune anemia?
NCT ID NCT07190261
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This early-phase study tests a new drug, enatumab, in 3 adults with relapsed or refractory warm antibody autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Current treatments often stop working or cause side effects. The goal is to see if enatumab can improve response rates and control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking union medical college hospital
Beijing, Shuangfuyuan, NO I., 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.